Season 12 · Episode 6
Michael Ackermann (Allergan) - A Tearful Tale of Biodesign
Entrepreneurial Thought Leaders (ETL) · STVP
November 16, 201656m 1s
Audio is streamed directly from the publisher (rss.art19.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Michael Ackermann, CEO of a med-tech startup that created a tear-stimulation device for those with dry-eye disease, explains how acquisition by a global pharmaceutical giant is helping him achieve his goal of reaching as many patients as possible. Ackermann, a graduate of the Stanford Byers Center for Biodesign, also discusses why big tech companies have yet to disrupt healthcare and how that translates into big opportunities for entrepreneurs.
Topics
acquisitionsdecision-makingtechnologystakeholdersgovernmentcomplexitycreativitydesignlife lessonsregulationsinnovationbiodesignstrategymed-techcultureinsurancechallengesleadershipentrepreneurshipengineeringhealthcaremedicinethought leadershipstartupsfoundersconsolidationsafetyuncertaintyjourneyETLstanford university